Should angiotensin-converting enzyme inhibitors be added to the water supply of patients with diabetes?

Endocrine Practice

Volumn 7, Issue 1, 2001, Pages 59-63

  Bell, D S H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIACYLGLYCEROL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INSULIN; ISRADIPINE; LISINOPRIL; NISOLDIPINE; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN; PROTEIN; PROTEIN KINASE C; RAMIPRIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; ANGIOTENSIN CONVERTING ENZYME INHIBITORS; WATER;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; HEART DISEASE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT PLANNING; WATER SUPPLY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; PROTEINURIA; RISK FACTOR;

ADULT; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DIABETIC ANGIOPATHIES; HEART DISEASES; HUMAN; HYPERTENSION; RISK FACTORS; WATER;

EID: 0034840495     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.7.1.59     Document Type: Article

References (40)

1. Effects of an angiotensin-converting-enzyme inhibitors, ramipril, on cardiovascular events in high-risk patients
2. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
3. Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy
4. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy
5. Current strategies for retarding progression of renal disease
6. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria
7. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus
8. Potential therapeutic approaches to the treatment of prevention of diabetic neuropathy: Evidence from experimental studies
9. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
11. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes
12. Protein kinase C activation and the development of diabetic complications
13. Angioedema due to ACE inhibitors: Increased risk in patients of African origin
14. Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM
15. Dealing with diabetic nephropathy
16. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes
17. Predicting diabetic nephropathy in insulin-dependent patients
18. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus
19. Endothelial dysfunction and inhibition of converting enzyme
20. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
21. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
22. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
23. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
24. Diabetes and cardiovascular disease: The Framingham Study
25. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
26. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomised trial
27. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and the MICRO-HOPE substudy
28. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
29. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
30. Isradipine in prediabetic hypertensive subjects
31. Treatment of hypertensive patients with diabetes
32. Antihypertensive therapy in type 2 diabetes: Implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) Trial
33. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
34. ACE inhibition and glucose transport in insulin-resistant muscle: Roles of bradykinin and nitric oxide
35. A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients
36. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells
37. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction
38. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
39. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors